These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 9839011)
1. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Lee YS; Chen Z; Kador PF Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011 [TBL] [Abstract][Full Text] [Related]
2. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461 [TBL] [Abstract][Full Text] [Related]
3. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479 [TBL] [Abstract][Full Text] [Related]
4. Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex. Sugiyama K; Chen Z; Lee YS; Kador PF Biochem Pharmacol; 2000 Feb; 59(4):329-36. PubMed ID: 10644040 [TBL] [Abstract][Full Text] [Related]
5. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors. Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328 [TBL] [Abstract][Full Text] [Related]
6. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme. El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717 [TBL] [Abstract][Full Text] [Related]
7. Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study. El-Sayed S; Metwally K; El-Shanawani AA; Abdel-Aziz LM; El-Rashedy AA; Soliman MES; Quattrini L; Coviello V; la Motta C Bioorg Med Chem Lett; 2017 Oct; 27(20):4760-4764. PubMed ID: 28935265 [TBL] [Abstract][Full Text] [Related]
8. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives. Celestina SK; Sundaram K; Ravi S Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs). Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248 [TBL] [Abstract][Full Text] [Related]
10. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor. El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464 [TBL] [Abstract][Full Text] [Related]
11. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis. Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169 [TBL] [Abstract][Full Text] [Related]
13. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. El-Kabbani O; Old SE; Ginell SL; Carper DA Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777 [TBL] [Abstract][Full Text] [Related]
14. Phenolic marine natural products as aldose reductase inhibitors. Manzanaro S; Salva J; de la Fuente JA J Nat Prod; 2006 Oct; 69(10):1485-7. PubMed ID: 17067167 [TBL] [Abstract][Full Text] [Related]
15. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. Kurono M; Fujiwara I; Yoshida K Biochemistry; 2001 Jul; 40(28):8216-26. PubMed ID: 11444967 [TBL] [Abstract][Full Text] [Related]
16. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography. Oka M; Matsumoto Y; Sugiyama S; Tsuruta N; Matsushima M J Med Chem; 2000 Jun; 43(12):2479-83. PubMed ID: 10882376 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of human aldehyde reductase: characterization of the active site pocket. Barski OA; Gabbay KH; Grimshaw CE; Bohren KM Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785 [TBL] [Abstract][Full Text] [Related]
18. 3D-pharmacophore analyses of aldose reductase inhibitory spiroquinazolinones. Nakao K; Asao M; Shirai H; Shimizu R Drug Des Discov; 1999 Aug; 16(2):155-63. PubMed ID: 10533811 [TBL] [Abstract][Full Text] [Related]
19. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors. Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015 [TBL] [Abstract][Full Text] [Related]
20. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. Nakano T; Petrash JM Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]